{"id":20662,"date":"2023-01-06T17:37:42","date_gmt":"2023-01-06T12:07:42","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=20662"},"modified":"2023-01-10T17:12:28","modified_gmt":"2023-01-10T11:42:28","slug":"osteomyelitis-treatment-outlook","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook","title":{"rendered":"Osteomyelitis Treatment Market: Evaluating the New Line of Therapies in the Therapeutics Space"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a12d53ee5e09\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a12d53ee5e09\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook\/#Current_Osteomyelitis_Treatment_Landscape_Urgent_Unmet_Need_for_Safe_and_Efficacious_Treatment\" >Current Osteomyelitis Treatment Landscape: Urgent Unmet Need for Safe and Efficacious Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook\/#Osteomyelitis_Pipeline_Promising_Albeit_Limited_Treatment_Options\" >Osteomyelitis Pipeline: Promising, Albeit Limited, Treatment Options<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook\/#The_Osteomyelitis_Treatment_Market_is_all_set_to_grow_at_a_Decent_Pace\" >The Osteomyelitis Treatment Market is all set to grow at a Decent Pace<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>A bone marrow infection that tends to spread and frequently involves periosteal tissues and nearby cortical plates is known as osteomyelitis. It might be acute, subacute, or chronic. In most cases, acute osteomyelitis is hematogenous in origin, has a recent onset, and has a brief duration. It can also be brought on by trauma, such as a compound fracture or puncture wound; its position can be in the diaphyseal, epiphyseal, or metaphyseal regions. Less pathogenic pathogens typically bring on long-lasting subacute osteomyelitis. The inability to effectively treat acute osteomyelitis leads to chronic osteomyelitis, which is marked by bone necrosis and sequestration.<\/p>\n\n\n\n<p>Over the last few decades, an upward trend in <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteomyelitis-epidemiology-forecast\">osteomyelitis cases<\/a> has been seen. This might be due to advancements in osteomyelitis diagnosis and increasing rates of certain risk factors, such as diabetes and the aging population. Patients with osteomyelitis may exhibit a wide range of symptoms, from an open wound revealing the shattered bone to no evident skin lesion but with accompanying swelling, bone pain, lower extremity warmth, and tenderness upon examination.&nbsp;<\/p>\n\n\n\n<p>In a study by <strong>Walter et al. (2021),<\/strong> osteomyelitis rates were quantified based on annual ICD-10 diagnosis codes from German medical institutions between 2008 and 2018, provided by the Federal Statistical Office of Germany (Destatis). The overall prevalence of osteomyelitis increased by <strong>10.44%<\/strong> from <strong>15.5 per 100,000<\/strong> to <strong>16.7 per 100,000<\/strong> inhabitants between 2008 and 2018. Out of <strong>11,340<\/strong> cases in 2018, <strong>47.6% <\/strong>were diagnosed as chronic, <strong>33.2%<\/strong> as acute, and <strong>19.2%<\/strong> as unspecified osteomyelitis. Men were more often affected than women, with <strong>63.4% <\/strong>of all cases compared to <strong>36.6%<\/strong>. The largest proportion of patients comprised the age group 60\u201369 (<strong>22.1%<\/strong>), followed by 70\u201379 (<strong>21.7%<\/strong>). More osteomyelitis diagnoses in older patients were observed. Lower extremities were most frequently infected, with <strong>73.8% <\/strong>of all cases in 2018 (<strong>+10.8%<\/strong> change).<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>As per the assessment done by DelveInsight in the latest published \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/osteomyelitis-epidemiology-forecast\">Osteomyelitis Epidemiology<\/a>\u201d report, there were approximately 93,000 cases in the US, 46,000 in the EU5, and 22,500 in Japan in 2021.&nbsp;<\/strong><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-current-osteomyelitis-treatment-landscape-urgent-unmet-need-for-safe-and-efficacious-treatment\"><span class=\"ez-toc-section\" id=\"Current_Osteomyelitis_Treatment_Landscape_Urgent_Unmet_Need_for_Safe_and_Efficacious_Treatment\"><\/span><strong>Current Osteomyelitis Treatment Landscape: Urgent Unmet Need for Safe and Efficacious Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Optimal osteomyelitis treatment of skeletal infections requires collaborative efforts of pediatricians, orthopedic surgeons, and interventional radiologists. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteomyelitis-market\">osteomyelitis treatment regimen<\/a> involves surgery, antibiotics, and painkiller. Antibiotics can make up an effective osteomyelitis treatment regimen but may include the surgical removal of dead bone in chronic osteomyelitis. Painkillers are given to ease the pain. In neglected cases with flexion contractures, prolonged physical therapy is required. Early osteomyelitis diagnosis is crucial because fast antibiotic delivery may prevent permanent bone loss. However, leading pharma companies, including <strong>Durata Therapeutics Inc, Allergan plc, Basilea Pharmaceutica, and Adaptive Phage Therapeutics, Inc.<\/strong>, are evaluating their lead assets in various stages of clinical development to improve the osteomyelitis treatment landscape.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06122250\/Osteomyelitis-Market-Assessment.png\" alt=\"Osteomyelitis Market Assessment\" class=\"wp-image-20667\" width=\"1000\" height=\"520\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06122250\/Osteomyelitis-Market-Assessment.png 1000w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06122250\/Osteomyelitis-Market-Assessment-300x156.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06122250\/Osteomyelitis-Market-Assessment-150x78.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06122250\/Osteomyelitis-Market-Assessment-768x399.png 768w\" sizes=\"(max-width: 1000px) 100vw, 1000px\" \/><figcaption class=\"wp-element-caption\"><strong>Key Insights into the Osteomyelitis Market <\/strong><\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Osteomyelitis_Pipeline_Promising_Albeit_Limited_Treatment_Options\"><\/span><strong>Osteomyelitis Pipeline: Promising, Albeit Limited, Treatment Options<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The osteomyelitis treatment space has witnessed several clinical trials coming to a halt due to unfavorable clinical outcomes. Although the <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteomyelitis-pipeline-insight\">current osteomyelitis pipeline<\/a> is restricted to just two products, they seem promising, having shown impressive results in other indications and gaining regulatory approval globally. The major late-stage products likely to hit the osteomyelitis treatment market include <strong>DALVANCE (dalbavancin) and Ceftobiprole medocaril. <\/strong>Improved methods of delivering antibiotics are being explored, and antimicrobial resistance remains a major challenge, compelling the development of novel therapeutics for osteomyelitis treatment.&nbsp;<\/p>\n\n\n\n<p><strong>DALVANCE (dalbavancin) <\/strong>is a second-generation, semi-synthetic lipoglycopeptide antibiotic consisting of a lipophilic side chain added to an enhanced glycopeptide backbone. It demonstrates bactericidal activity <em>in vitro<\/em> against a range of Gram-positive bacteria, such as <em>S. aureus<\/em> (including methicillin-resistant, also known as MRSA, strains) and <em>S. pyogenes,<\/em> as certain other streptococcal species. It is expected to enter the US market by 2026.&nbsp;<\/p>\n\n\n\n<p><strong>Ceftobiprole medocaril <\/strong>is a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. This includes methicillin-susceptible and resistant <em>S. aureus<\/em> (MSSA, MRSA) and susceptible <em>Pseudomonas spp<\/em>. In June 2022, Basilea announced positive topline results for the Phase III ERADICATE study, evaluating ceftobiprole in treating adult patients with bacterial bloodstream infections caused by <em>Staphylococcus aureus<\/em> (SAB). Basilea is planning to submit a New Drug Application (NDA) for ceftobiprole to the FDA around 2022 end.<\/p>\n\n\n\n<p>A phage therapy by <strong>Adaptive Phage Therapeutic (APT)<\/strong> is also being evaluated in Phase I\/II osteomyelitis clinical trial. A single phage strain can generally infect only a single bacterial strain. Thus, in contrast to antibiotics which are effective against many different organisms, a purified phage strain is limited but highly effective against the strain of bacteria it can lyse. If bacterial resistance emerges in response to the initial phage administration, Adaptive Phage Therapeutic (APT) can rapidly identify a new phage effective against the mutated strain. This process can be continued until the bacterial infection is cured.<\/p>\n\n\n\n<p>Other than these candidates, no other pharmaceutical player is in the late-stage development of an improved version of existing osteomyelitis treatments or novel treatment alternatives; however, some research organizations and university-based trials are underway. Rising <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteomyelitis-epidemiology-forecast\">osteomyelitis prevalence<\/a> due to the increasing age of the general population and burgeoning exposure to risk factors (e.g., obesity, tobacco, and kidney disease) is expected to impact the osteomyelitis treatment market landscape in the upcoming years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Osteomyelitis_Treatment_Market_is_all_set_to_grow_at_a_Decent_Pace\"><\/span><strong>The Osteomyelitis Treatment Market is all set to grow at a Decent Pace<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>According to DelveInsight\u2019s analysis, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteomyelitis-market\">osteomyelitis market<\/a> was valued at approximately <strong>USD 400 million<\/strong> in 2021 and is expected to reach <strong>USD 650 million <\/strong>by 2032 at a<strong> CAGR of 4.4%.<\/strong> The development of disease-specific therapies for osteomyelitis will auger well for the market landscape, which will likely bring significant changes in the osteomyelitis treatment space during the forecast period (2019\u20132032). However, further research into current healthcare pathways clearly shows a need for further therapeutic trials to improve osteomyelitis treatment options. Moreover, a better understanding of disease pathophysiology, etiology, and progression of the disease has enriched the clinical practice. As there is no approved drug for osteomyelitis treatment available in the market, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteomyelitis-pipeline-insight\">first product approved for osteomyelitis treatment<\/a> will get the first mover advantage in the osteomyelitis treatment market.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/osteomyelitis-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06122117\/osteomyelitis-market-outlook-1024x256.png\" alt=\"osteomyelitis market outlook\" class=\"wp-image-20666\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06122117\/osteomyelitis-market-outlook-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06122117\/osteomyelitis-market-outlook-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06122117\/osteomyelitis-market-outlook-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06122117\/osteomyelitis-market-outlook-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06122117\/osteomyelitis-market-outlook-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06122117\/osteomyelitis-market-outlook-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06122117\/osteomyelitis-market-outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1672986567372\"><strong class=\"schema-faq-question\"><strong>1. What is osteomyelitis?<\/strong><\/strong> <p class=\"schema-faq-answer\">Osteomyelitis is an acute infection of the bone caused by a pathogen\u2019s direct or indirect invasion. Direct invasion, also known as exogenous or acute contagious osteomyelitis, can occur at any time if the body has an open wound.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1672986588377\"><strong class=\"schema-faq-question\"><strong>2. What are the osteomyelitis symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">Osteomyelitis symptoms can be nonspecific and difficult to identify. Chronic pain, persistent sinus or wound drainage, poor wound healing, malaise, and, in some cases, fever are among them. The clinical manifestation of osteomyelitis is determined by the etiology.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1672986618574\"><strong class=\"schema-faq-question\"><strong>3. What causes osteomyelitis?<\/strong><\/strong> <p class=\"schema-faq-answer\">The most common cause of acute and chronic hematogenous osteomyelitis in adults and children is <em>Staphylococcus aureus<\/em>. The next most common pathogens in children are Group A <em>Streptococcus, Streptococcus pneumoniae, <\/em>and <em>Kingella kingae<\/em>.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1672986631500\"><strong class=\"schema-faq-question\"><strong>4. How is osteomyelitis diagnosed?<\/strong><\/strong> <p class=\"schema-faq-answer\">Adult osteomyelitis diagnosis can be difficult. A high level of clinical suspicion is required, as well as appropriate cultures and imaging studies.\u00a0<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1672986645244\"><strong class=\"schema-faq-question\"><strong>5. How many pharma companies are working in the osteomyelitis treatment landscape?<\/strong><\/strong> <p class=\"schema-faq-answer\">Key pharma companies such as Durata Therapeutics Inc, Allergan plc, Basilea Pharmaceutica, and Adaptive Phage Therapeutics, Inc. are currently working in the osteomyelitis treatment market.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>A bone marrow infection that tends to spread and frequently involves periosteal tissues and nearby cortical plates is known as osteomyelitis. It might be acute, subacute, or chronic. In most cases, acute osteomyelitis is hematogenous in origin, has a recent onset, and has a brief duration. It can also be brought on by trauma, such [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":20663,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":5,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[20124,20128,20126,20127,20125,20129],"industry":[17225],"therapeutic_areas":[17231],"class_list":["post-20662","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-osteomyelitis","tag-osteomyelitis-clinical-trials","tag-osteomyelitis-market","tag-osteomyelitis-pipeline","tag-osteomyelitis-treatment","tag-osteomyelitis-treatment-market","industry-pharmaceutical","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Investigating the Pipeline for Osteomyelitis Treatment Landscape<\/title>\n<meta name=\"description\" content=\"Osteomyelitis treatment pipeline is restricted but seems promising, having shown impressive results and gaining regulatory approval globally\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investigating the Pipeline for Osteomyelitis Treatment Landscape\" \/>\n<meta property=\"og:description\" content=\"Osteomyelitis treatment pipeline is restricted but seems promising, having shown impressive results and gaining regulatory approval globally\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-06T12:07:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-10T11:42:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06121913\/osteomyelitis-treatment-outlook.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Investigating the Pipeline for Osteomyelitis Treatment Landscape","description":"Osteomyelitis treatment pipeline is restricted but seems promising, having shown impressive results and gaining regulatory approval globally","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook","og_locale":"en_US","og_type":"article","og_title":"Investigating the Pipeline for Osteomyelitis Treatment Landscape","og_description":"Osteomyelitis treatment pipeline is restricted but seems promising, having shown impressive results and gaining regulatory approval globally","og_url":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-01-06T12:07:42+00:00","article_modified_time":"2023-01-10T11:42:28+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06121913\/osteomyelitis-treatment-outlook.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook","url":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook","name":"Investigating the Pipeline for Osteomyelitis Treatment Landscape","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06121913\/osteomyelitis-treatment-outlook.png","datePublished":"2023-01-06T12:07:42+00:00","dateModified":"2023-01-10T11:42:28+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Osteomyelitis treatment pipeline is restricted but seems promising, having shown impressive results and gaining regulatory approval globally","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#faq-question-1672986567372"},{"@id":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#faq-question-1672986588377"},{"@id":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#faq-question-1672986618574"},{"@id":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#faq-question-1672986631500"},{"@id":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#faq-question-1672986645244"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06121913\/osteomyelitis-treatment-outlook.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06121913\/osteomyelitis-treatment-outlook.png","width":772,"height":482,"caption":"osteomyelitis-treatment-outlook"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#faq-question-1672986567372","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#faq-question-1672986567372","name":"1. What is osteomyelitis?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Osteomyelitis is an acute infection of the bone caused by a pathogen\u2019s direct or indirect invasion. Direct invasion, also known as exogenous or acute contagious osteomyelitis, can occur at any time if the body has an open wound.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#faq-question-1672986588377","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#faq-question-1672986588377","name":"2. What are the osteomyelitis symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Osteomyelitis symptoms can be nonspecific and difficult to identify. Chronic pain, persistent sinus or wound drainage, poor wound healing, malaise, and, in some cases, fever are among them. The clinical manifestation of osteomyelitis is determined by the etiology.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#faq-question-1672986618574","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#faq-question-1672986618574","name":"3. What causes osteomyelitis?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The most common cause of acute and chronic hematogenous osteomyelitis in adults and children is <em>Staphylococcus aureus<\/em>. The next most common pathogens in children are Group A <em>Streptococcus, Streptococcus pneumoniae, <\/em>and <em>Kingella kingae<\/em>.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#faq-question-1672986631500","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#faq-question-1672986631500","name":"4. How is osteomyelitis diagnosed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Adult osteomyelitis diagnosis can be difficult. A high level of clinical suspicion is required, as well as appropriate cultures and imaging studies.\u00a0","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#faq-question-1672986645244","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/osteomyelitis-treatment-outlook#faq-question-1672986645244","name":"5. How many pharma companies are working in the osteomyelitis treatment landscape?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Key pharma companies such as Durata Therapeutics Inc, Allergan plc, Basilea Pharmaceutica, and Adaptive Phage Therapeutics, Inc. are currently working in the osteomyelitis treatment market.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/06121913\/osteomyelitis-treatment-outlook-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Osteomyelitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Osteomyelitis clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Osteomyelitis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Osteomyelitis pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Osteomyelitis treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Osteomyelitis treatment market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Osteomyelitis<\/span>","<span class=\"advgb-post-tax-term\">Osteomyelitis clinical trials<\/span>","<span class=\"advgb-post-tax-term\">Osteomyelitis market<\/span>","<span class=\"advgb-post-tax-term\">Osteomyelitis pipeline<\/span>","<span class=\"advgb-post-tax-term\">Osteomyelitis treatment<\/span>","<span class=\"advgb-post-tax-term\">Osteomyelitis treatment market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jan 6, 2023","modified":"Updated on Jan 10, 2023"},"absolute_dates_time":{"created":"Posted on Jan 6, 2023 5:37 pm","modified":"Updated on Jan 10, 2023 5:12 pm"},"featured_img_caption":"osteomyelitis-treatment-outlook","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=20662"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20662\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/20663"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=20662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=20662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=20662"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=20662"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=20662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}